<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034969</url>
  </required_header>
  <id_info>
    <org_study_id>JE049-5134</org_study_id>
    <nct_id>NCT01034969</nct_id>
  </id_info>
  <brief_title>Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)</brief_title>
  <official_title>Icatibant Outcome Survey (IOS) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed
      to document the routine clinical outcomes over time in participants with angioedema treated
      with Firazyr® (icatibant) and/or Cinryze® (C1 inhibitor [human]) in countries where it is
      currently approved. The data collected will be used to evaluate the safety of Firazyr
      (icatibant) and Cinryze (C1 inhibitor [human]) in routine clinical practice and as a data
      source for post-marketing investigations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Icatibant Outcome Survey (IOS) is a multicenter, prospective, observational study for
      participants treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in
      countries where it is currently approved. The entry of participants in the Icatibant Outcome
      Survey (IOS) is at the discretion of the physician and the participant and is not a
      pre-requisite for prescribing Firazyr (icatibant) or Cinryze (C1 inhibitor [human]).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2009</start_date>
  <completion_date type="Anticipated">May 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Cardiac Ischemia Events in Participants Predisposed to Cardiac Ischemia Events With Concomitant Firazyr (Icatibant) Administration</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Incidence of cardiac ischemia events in participants predisposed to cardiac ischemia events with concomitant Firazyr (Icatibant) administration will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hypotension for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Incidence of hypotension for Firazyr (Icatibant) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Swelling of Mucous Membranes for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Incidence of swelling of mucous membranes for Firazyr (Icatibant) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Bronchoconstriction for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Incidence of bronchoconstriction for Firazyr (Icatibant) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Aggravation of Pain for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Incidence of aggravation of pain for Firazyr (Icatibant) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Hormones Level Measurements- Tanner Staging for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Effects on sexual maturation in pubertal adolescents will be measured using Tanner staging (pubic hair stage and genital breast stage) for Firazyr (Icatibant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Complete Resolution of the Firazyr (Icatibant)-Treated Laryngeal Attacks</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Time to complete resolution of the laryngeal attacks will be assessed. It is defined as the time between the first injection of treatment and the complete resolution of all symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AE) Related to Firazyr (Icatibant)-Treated Laryngeal Attacks</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An AE is defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in the registry, whether or not considered product-related. This includes an exacerbation of a pre-existing condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reactions (ADR) for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An ADR is a response to a medicinal product that is noxious and unintended and that occurs at doses normally used in man for prophylaxis, diagnosis, and treatment of disease or for the restoration, correction, or modification of physiological function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE) for Firazyr (Icatibant)</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An AE or ADR that meets 1 or more of the following criteria or outcomes is classified as an SAE whether considered to be related to the pharmaceutical product or not: death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; a congenital anomaly or birth defect; important medical events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pregnancy and Lactation Events During Firazyr (Icatibant) Exposure</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>The incidence of pregnancy or lactation events coinciding with exposure to Firazyr (Icatibant) will be summarized by angioedema treatment and subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AE) for Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An AE is defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in the registry, whether or not considered product-related. This includes an exacerbation of a pre-existing condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reactions (ADR) for Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An ADR is a response to a medicinal product that is noxious and unintended and that occurs at doses normally used in man for prophylaxis, diagnosis, and treatment of disease or for the restoration, correction, or modification of physiological function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE) for Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>An AE or ADR that meets 1 or more of the following criteria or outcomes is classified as an SAE whether considered to be related to the pharmaceutical product or not: death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; a congenital anomaly or birth defect; important medical events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Thrombotic or Thromboembolic Events for Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Thrombotic or thromboembolic events will be reported as SAEs and will include, but are not limited to, established diagnoses of any of the following: renal allograft arterial or venous thrombosis; deep vein thrombosis; myocardial infarction; pulmonary embolism; Ischemic cerebrovascular accident (stroke)- cerebrovascular accident exclusive of cerebrovascular hemorrhage (subarachnoid or subdural hemorrhage); any large vessel thrombosis; thrombophlebitis; catheter-related thrombotic events (including clotted dialysis access grafts) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pregnancy and Lactation Events During Cinryze (C1 Inhibitor [Human]) Exposure</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>The incidence of pregnancy or lactation events coinciding with exposure to Cinryze (C1 inhibitor [human]) will be summarized by angioedema treatment and subgroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Exposure Data for Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Drug exposure data for Cinryze (C1 inhibitor [human]) for prophylaxis, pre-procedural, and acute treatments will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Hereditary Angioedema (HAE) Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Frequency of HAE attacks in participants treated with Cinryze (C1 inhibitor [human]) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Severity of HAE attacks in participants treated with Cinryze (C1 inhibitor [human]) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anatomic Location of Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Anatomic location of HAE attacks in participants treated with Cinryze (C1 inhibitor [human]) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of Severe or Laryngeal Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Outcome of severe or laryngeal HAE attacks in participants treated with Cinryze (C1 inhibitor [human]) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of Hereditary Angioedema Attacks for Treatment With Cinryze (C1 Inhibitor [Human])</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Outcome of HAE attacks for treatment with Cinryze (C1 inhibitor [human]) which was initiated more than 4 hours after onset of the attack will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment For Attack</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Time to treatment for attack will be assessed. It is defined as the time between the onset of the attack and the first injection of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Resolution of Attack</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Time to complete resolution of attack will be assessed. It is defined as the time between the first injection of treatment and the complete resolution of all symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Attack</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>Total duration of attack will be assessed. It is defined as the time between the onset of the attack and the complete resolution of all symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hereditary Angioedema-Treated Attacks</measure>
    <time_frame>From enrollment through study participation (Approximately 13 years)</time_frame>
    <description>The frequency, severity, and affected sites of HAE-treated attacks will be reported.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Participants with hereditary angioedema (HAE)</arm_group_label>
    <description>All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Type I or II HAE, and, where applicable, with angiotensin-converting
        enzyme inhibitor (ACE-I)-induced angioedema, non-histaminergic idiopathic angioedema, or
        acquired angioedema, irrespective of treatment and/or other treatments and also
        participants who have taken at least 1 dose of Firazyr (Icatibant) or Cinryze (C1 inhibitor
        [human]) will be included in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of at least 1 of the following:

               -  Hereditary angioedema (HAE) type I or II

               -  HAE with normal C1 inhibitor

               -  ACE-I-induced angioedema

               -  Non-histaminergic idiopathic angioedema

               -  Acquired angioedema.

          2. Signed and dated written informed consent from the participant or, for participants
             aged less than(&lt;)18 years (or as per local regulation, such as &lt;16 years in the United
             Kingdom [UK]), parent and/or participants legally authorized representative (LAR), and
             assent of the minor where applicable.

          3. At sites only participating in the drug registry, participants must have taken at
             least 1 dose of Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]).

          4. Enrolled participants in Germany taking Firazyr (Icatibant) or Cinryze (C1 inhibitor
             [human]) will only use the respective product in accordance with the product label.

        Exclusion Criteria:

          1. Participants enrolled in clinical trials where the product is blinded or where the
             product under investigation is for the treatment of HAE, ACE-I-induced angioedema,
             non-histaminergic idiopathic angioedema, or acquired angioedema.

          2. Participants enrolled in another Shire-sponsored registry involving products for the
             treatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema,
             or acquired angioedema. An exception applies to participants enrolled in the Shire
             lanadelumab ENABLE study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Development Center Americas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Development Center Americas Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Campbelltown Hospital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61246343000</phone>
    </contact>
    <investigator>
      <last_name>Constance Katelaris, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61882223369</phone>
    </contact>
    <investigator>
      <last_name>William Smith, MD, MBBS, FRACP, FRCPA, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+433163809618</phone>
    </contact>
    <investigator>
      <last_name>Lukas Koch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina Do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+551149946900</phone>
      <email>asgrumach@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anete Grumach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+420543182658</phone>
    </contact>
    <investigator>
      <last_name>Roman Hakl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers Cedex 10</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33241353544</phone>
      <email>lumartin@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33298347600</phone>
    </contact>
    <investigator>
      <last_name>Claire De Moreuil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>site contact</last_name>
      <phone>+33476768947</phone>
    </contact>
    <investigator>
      <last_name>Laurence Bouillet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans cedex 9</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33244710750</phone>
    </contact>
    <investigator>
      <last_name>Herve Maillard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Update</last_name>
      <phone>+33320445765</phone>
    </contact>
    <investigator>
      <last_name>David Launay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33472117565</phone>
    </contact>
    <investigator>
      <last_name>Magali Aubineau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy-Hopital Brabois Adulte</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Archet I</name>
      <address>
        <city>Nice</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33492035823</phone>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Jeandel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Georges Renon</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>33549783560</phone>
      <email>lucile.sorin@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Lucile Sorin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu de Paris Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33142160465</phone>
    </contact>
    <investigator>
      <last_name>Olivier Fain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hals-Nasen-Ohrenklinik und Poliklinik</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+498941409592</phone>
    </contact>
    <investigator>
      <last_name>Ulrich Strassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang Goethe-Universitat</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+496963016439</phone>
    </contact>
    <investigator>
      <last_name>Emel Aygören-Pürsün, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+496131170</phone>
    </contact>
    <investigator>
      <last_name>Petra Staubach-Renz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493514580</phone>
    </contact>
    <investigator>
      <last_name>Andrea Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493045050</phone>
    </contact>
    <investigator>
      <last_name>Markus Magerl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hämophilie Zentrum Rhein Main GmbH</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4961059638909</phone>
    </contact>
    <investigator>
      <last_name>Inmaculada Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4973150026745</phone>
      <email>jens.greve@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Jens Greve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navy Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302107261301</phone>
    </contact>
    <investigator>
      <last_name>Fotios Psarros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302310693350</phone>
    </contact>
    <investigator>
      <last_name>Efimia Papadopoulou Alataki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Niall Conlon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>972 549706516</phone>
    </contact>
    <investigator>
      <last_name>Aharon Kessel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - PPDS</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center - PPDS</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+97235343888</phone>
    </contact>
    <investigator>
      <last_name>Nancy Agmon-Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center PPDS</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+972524498779</phone>
    </contact>
    <investigator>
      <last_name>Shmuel Kivity, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Arturo Genovese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390239042757</phone>
    </contact>
    <investigator>
      <last_name>Andrea Zanichelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Ospedale Policlinico Consorziale Di Bari</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390805592784</phone>
    </contact>
    <investigator>
      <last_name>Anna Maria Di Palma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Policlinico Di Monserrato</name>
      <address>
        <city>Monserrato</city>
        <state>Sardegna</state>
        <zip>9042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3907051096015</phone>
      <email>davidefirinu@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Davide Firinu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHUS - H. Clinico U. de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de La Marina Baixa</name>
      <address>
        <city>Villajoyosa</city>
        <state>Alicante</state>
        <zip>03570</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34966859800</phone>
    </contact>
    <investigator>
      <last_name>Carlos Hernando de Larramendi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932607500</phone>
      <email>rlleonart@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Lleonart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932746000</phone>
    </contact>
    <investigator>
      <last_name>Mar Guilarte, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932607680</phone>
      <email>rlleonart@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Lleonart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cruz Roja Española de Gijón</name>
      <address>
        <city>Gijon</city>
        <zip>33202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34953008000</phone>
    </contact>
    <investigator>
      <last_name>Blanca Saenz de San Pedro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34973727222</phone>
      <email>lmarques@gss.scs.es</email>
    </contact>
    <investigator>
      <last_name>Lluis Marques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Resolución de Procesos Asistenciales (C.A.R.P.A.)</name>
      <address>
        <city>Logrono</city>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34941296041</phone>
    </contact>
    <investigator>
      <last_name>Teofilo Lobera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34915868000</phone>
    </contact>
    <investigator>
      <last_name>Maria Luisa Baeza, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34917271785</phone>
    </contact>
    <investigator>
      <last_name>M Teresa Caballero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio - PPDS</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34955013622</phone>
    </contact>
    <investigator>
      <last_name>Teresa González-Quevedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34961244084</phone>
    </contact>
    <investigator>
      <last_name>Dolores Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <zip>SE-55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441223400185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441865741166</phone>
    </contact>
    <investigator>
      <last_name>Rashmi Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441276604604</phone>
    </contact>
    <investigator>
      <last_name>Patrick Yong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>York</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+01132065567</phone>
    </contact>
    <investigator>
      <last_name>Sinisa Savic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441214241635</phone>
    </contact>
    <investigator>
      <last_name>Anjali Ekbote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales - PPDS</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442920743444</phone>
    </contact>
    <investigator>
      <last_name>Tariq El-Shanawany, MBBS, MD, MRCPCH, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4420737770003382</phone>
    </contact>
    <investigator>
      <last_name>Sorena Kiani, FRCP, FRCPath, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442079411836</phone>
    </contact>
    <investigator>
      <last_name>Suranjith Seneviratne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary - PPDS</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441612761234</phone>
    </contact>
    <investigator>
      <last_name>Tomaz Garcez Pereira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441912825452</phone>
    </contact>
    <investigator>
      <last_name>Catherine Stroud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441752792555</phone>
    </contact>
    <investigator>
      <last_name>Claire Bethune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary angioedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

